Compare JACK & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JACK | NGEN |
|---|---|---|
| Founded | 1951 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.2M | 317.6M |
| IPO Year | 1994 | N/A |
| Metric | JACK | NGEN |
|---|---|---|
| Price | $11.61 | $3.98 |
| Analyst Decision | Hold | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $23.47 | N/A |
| AVG Volume (30 Days) | ★ 766.7K | 99.9K |
| Earning Date | 02-18-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,465,314,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.58 | $3.55 |
| 52 Week High | $31.25 | $5.93 |
| Indicator | JACK | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 19.57 | 45.25 |
| Support Level | N/A | $3.69 |
| Resistance Level | $20.96 | $4.44 |
| Average True Range (ATR) | 0.64 | 0.28 |
| MACD | -0.20 | 0.02 |
| Stochastic Oscillator | 1.20 | 52.86 |
Jack In The Box Inc operates quick-service restaurants and fast-casual restaurants across various states in the United States of America. Its core business includes the Jack in the Box hamburger chain, known for a broad menu that features hamburgers, tacos, sandwiches, salads, and breakfast items. The company also operates the Del Taco brand, which offers a variety of both Mexican and American favorites such as burritos and fries. These foods are available with the option of customization as per customer requirements. The company also offers catering and delivery services to its customers. Jack in the Box and Del Taco restaurant brands are the two reportable operating segments, of which, Jack in the Box generates maximum revenue for the company.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.